TY - JOUR
T1 - Blood pressure variability and outcome after acute intracerebral haemorrhage
T2 - A post-hoc analysis of INTERACT2, a randomised controlled trial
AU - Manning, Lisa
AU - Hirakawa, Yoichiro
AU - Arima, Hisatomi
AU - Wang, Xia
AU - Chalmers, John
AU - Wang, Jiguang
AU - Lindley, Richard
AU - Heeley, Emma
AU - Delcourt, Candice
AU - Neal, Bruce
AU - Lavados, Pablo
AU - Davis, Stephen M.
AU - Tzourio, Christophe
AU - Huang, Yining
AU - Stapf, Christian
AU - Woodward, Mark
AU - Rothwell, Peter M.
AU - Robinson, Thompson G.
AU - Anderson, Craig S.
N1 - Funding Information:
The INTERACT2 study was supported by grants ( 571281, 512402, and 1004170 ) from the National Health and Medical Research Council of Australia . LM is supported by a programme grant from the British Heart Foundation and United Kingdom Stroke Association ( TSA BHF 2012/01 ). YH holds a fellowship from the Uehara Memorial Foundation of Japan. HA holds an Australian Research Council Future Fellowship; MW holds a National Health and Medical Research Council Senior Research Fellowship; BN holds an Australian Research Council Future Fellowship and an National Health and Medical Research Council Senior Research Fellowship. CSA holds a National Health and Medical Research Council Senior Principal Research Fellowship.
Funding Information:
YH has been reimbursed for travel expenses from Osaka Pharmaceuticals. JW has received consulting fees from Novartis, Omron Healthcare, Pfizer, and Takeda; grant support from Novartis, Omron Healthcare, and Pfizer; lecture fees from A&D Pharma, Omron Healthcare, Novartis, Pfizer, and Servier; and reimbursement for travel expenses from Pfizer and Takeda. The other authors declare that they have no competing interests.
PY - 2014/4
Y1 - 2014/4
N2 - Background: High blood pressure is a prognostic factor for acute stroke, but blood pressure variability might also independently predict outcome. We assessed the prognostic value of blood pressure variability in participants of INTERACT2, an open-label randomised controlled trial (ClinicalTrials.gov number NCT00716079). Methods: INTERACT2 enrolled 2839 adults with spontaneous intracerebral haemorrhage (ICH) and high systolic blood pressure (150-220 mm Hg) without a definite indication or contraindication to early intensive treatment to reduce blood pressure. Participants were randomly assigned to intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs) or guideline-recommended treatment (target systolic blood pressure <180 mm Hg) within 6 h of onset of ICH. The primary outcome was death or major disability at 90 days (modified Rankin Scale score ≥3) and the secondary outcome was an ordinal shift in modified Rankin Scale scores at 90 days, assessed by investigators masked to treatment allocation. Blood pressure variability was defined according to standard criteria: five measurements were taken in the first 24 h (hyperacute phase) and 12 over days 2-7 (acute phase). We estimated associations between blood pressure variability and outcomes with logistic and proportional odds regression models. The key parameter for blood pressure variability was standard deviation (SD) of systolic blood pressure, categorised into quintiles. Findings: We studied 2645 (93·2%) participants in the hyperacute phase and 2347 (82·7%) in the acute phase. In both treatment cohorts combined, SD of systolic blood pressure had a significant linear association with the primary outcome for both the hyperacute phase (highest quintile adjusted OR 1·41, 95% CI 1·05-1·90; ptrend=·0167) and the acute phase (highest quintile adjusted OR 1·57, 95% CI 1·14-2·17; ptrend=·0124). The strongest predictors of outcome were maximum systolic blood pressure in the hyperacute phase and SD of systolic blood pressure in the acute phase. Associations were similar for the secondary outcome (for the hyperacute phase, highest quintile adjusted OR 1·43, 95% CI 1·14-1·80; ptrend=·0014; for the acute phase OR 1·46, 95% CI 1·13-1·88; ptrend=·0044). Interpretation: Systolic blood pressure variability seems to predict a poor outcome in patients with acute intracerebral haemorrhage. The benefits of early treatment to reduce systolic blood pressure to 140 mm Hg might be enhanced by smooth and sustained control, and particularly by avoiding peaks in systolic blood pressure.
AB - Background: High blood pressure is a prognostic factor for acute stroke, but blood pressure variability might also independently predict outcome. We assessed the prognostic value of blood pressure variability in participants of INTERACT2, an open-label randomised controlled trial (ClinicalTrials.gov number NCT00716079). Methods: INTERACT2 enrolled 2839 adults with spontaneous intracerebral haemorrhage (ICH) and high systolic blood pressure (150-220 mm Hg) without a definite indication or contraindication to early intensive treatment to reduce blood pressure. Participants were randomly assigned to intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs) or guideline-recommended treatment (target systolic blood pressure <180 mm Hg) within 6 h of onset of ICH. The primary outcome was death or major disability at 90 days (modified Rankin Scale score ≥3) and the secondary outcome was an ordinal shift in modified Rankin Scale scores at 90 days, assessed by investigators masked to treatment allocation. Blood pressure variability was defined according to standard criteria: five measurements were taken in the first 24 h (hyperacute phase) and 12 over days 2-7 (acute phase). We estimated associations between blood pressure variability and outcomes with logistic and proportional odds regression models. The key parameter for blood pressure variability was standard deviation (SD) of systolic blood pressure, categorised into quintiles. Findings: We studied 2645 (93·2%) participants in the hyperacute phase and 2347 (82·7%) in the acute phase. In both treatment cohorts combined, SD of systolic blood pressure had a significant linear association with the primary outcome for both the hyperacute phase (highest quintile adjusted OR 1·41, 95% CI 1·05-1·90; ptrend=·0167) and the acute phase (highest quintile adjusted OR 1·57, 95% CI 1·14-2·17; ptrend=·0124). The strongest predictors of outcome were maximum systolic blood pressure in the hyperacute phase and SD of systolic blood pressure in the acute phase. Associations were similar for the secondary outcome (for the hyperacute phase, highest quintile adjusted OR 1·43, 95% CI 1·14-1·80; ptrend=·0014; for the acute phase OR 1·46, 95% CI 1·13-1·88; ptrend=·0044). Interpretation: Systolic blood pressure variability seems to predict a poor outcome in patients with acute intracerebral haemorrhage. The benefits of early treatment to reduce systolic blood pressure to 140 mm Hg might be enhanced by smooth and sustained control, and particularly by avoiding peaks in systolic blood pressure.
UR - http://www.scopus.com/inward/record.url?scp=84896066836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896066836&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(14)70018-3
DO - 10.1016/S1474-4422(14)70018-3
M3 - Article
C2 - 24530176
AN - SCOPUS:84896066836
SN - 1474-4422
VL - 13
SP - 364
EP - 373
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 4
ER -